1 completed, 1 recruiting, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow Overweight Subject: new trials by email Literature Review of Overweight Subject trials Research Report on Overweight Subject
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin Metformin, Empagliflozin, Midazolam - Overweight Subject, Healthy Subjects | Phase 1 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 111 | 2025-09-24 | 2026-01-09 |
| Longitudinal Tracking Study on the Path Evolution of College Students' Proactive Health Behaviors Based on the "Environment-Psychology-Behavior" Three-Dimensional Coupling Model Overweight Subject | Completed | Yingying Tan | 80 | 2025-09-14 | 2026-10-08 | |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. Repaglinide, Atorvastatin, Digoxin - Healthy Adult Subject, Overweight Subject | Phase 1 | Unknown | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 30 | 2024-10-01 | 2024-09-23 |
Atorvastatin (1) · Digoxin (1) · Metformin (1) · Midazolam (1) · Rosuvastatin Calcium (1) · Valsartan (1) · Warfarin (1) · empagliflozin (1) · repaglinide (1)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (2) · Yingying Tan (1)
China (3)